"US drugmaker Pfizer is to buy rival Wyeth in a deal worth $68bn (£50bn), the two companies have announced. The merger will allow Pfizer to protect itself from a drop in revenues when its popular drug Lipitor and other products lose patent protection. It will also help Pfizer diversify its product portfolio, thanks to Wyeth's presence in biotech drugs and vaccines. Pfizer also announced plans to cut 10% of its global workforce, or 8,000 jobs, and shut some manufacturing sites" - BBCThis is the blog for CARG, the Coronary Artery Rehabilitation Group, based in Saskatoon, Saskatchewan, Canada. It will contain items of interest to CARG's own members and anybody else interested in the latest news about rehabilitation and heart-related matters. Canadian charitable number: 89675 0163 RR 0001 || e-mail: carg.ca@gmail.com || website: carg.ca || Blog disclaimer
Monday, January 26, 2009
Pfizer acquires Wyeth for $68bn
"US drugmaker Pfizer is to buy rival Wyeth in a deal worth $68bn (£50bn), the two companies have announced. The merger will allow Pfizer to protect itself from a drop in revenues when its popular drug Lipitor and other products lose patent protection. It will also help Pfizer diversify its product portfolio, thanks to Wyeth's presence in biotech drugs and vaccines. Pfizer also announced plans to cut 10% of its global workforce, or 8,000 jobs, and shut some manufacturing sites" - BBC
No comments:
Post a Comment